With progress plateauing for a second consecutive year and global financing also levelling off, the WHO has called for a ‘high burden to high impact’ country-led strategy.
Browsing: Parasitic > Malaria
Researchers from Imperial College London have reported their recent success in using ‘gene drive’ technology to block female mosquito reproduction, resulting in the total collapse of caged populations of Anopheles gambiae in as little as 7–11 generations.
A team of researchers from Imperial College London (UK) have identified compounds which prevent the malarial parasite sexually maturing inside the mosquito.
Genomics is increasingly being adopted into both research and clinical settings. Here, we speak to Dyann Wirth about the use of genomics in the field of malaria, from what it can uncover about the parasite to the hurdles that need to be overcome moving towards elimination.
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
Cerebral malaria is the most severe neurological complication of Plasmodium falciparum infection. Here, the authors discuss how NRG-1 could attenuate brain injury and mortality.
The US FDA have approved Krintafel (tafenoquine) for the radical cure of Plasmodium vivax malaria infections, the first approval for such a drug in 50 years.
Following a five decade-long battle against malaria, Paraguay has received certification from the WHO as having eliminated the disease.
A new study has estimated that up to 30% of parasite burden could be in the liver and bone marrow of infected individuals, a reservoir that has previously gone undetected and unstudied.